SANUWAVE, Inc. Provides Update On Patient Enrollment - Over 75 Percent Now Enrolled In Pivotal Dermapace Clinical Trial
1/29/2014 8:50:09 AM
ALPHARETTA, Ga., Jan. 29, 2014 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that it has enrolled over seventy-five percent (75%) of the minimum required patients in the Phase III supplemental clinical trial evaluating the dermaPACE® device on patients with diabetic foot ulcers. The clinical trial is designed to enroll a minimum of 90 patients; which is on track to occur in the first quarter of 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by